Trial Profile
A Randomized, Double-Blind, Positive-Controlled, Placebo-Controlled, 4-Period Crossover Study to Investigate the Electrocardiographic Effects of BMS-986165 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2022
Price :
$35
*
At a glance
- Drugs Deucravacitinib (Primary) ; Moxifloxacin
- Indications Autoimmune disorders; Crohn's disease; Cutaneous lupus erythematosus; Discoid lupus erythematosus; Lupus nephritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 01 Apr 2022 Results published in the Clinical Pharmacology in Drug Development
- 27 Sep 2018 Status changed from recruiting to completed.
- 17 Jul 2018 Status changed from not yet recruiting to recruiting.